Emerging therapeutic agents to lower lipoprotein (a) levels
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Recent epidemiological and genetic studies have suggested that lipoprotein (a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD). There is now interest in evaluating Lp(a) as a therapeutic target. This review will summarize emerging therapeutic agents to lower Lp(a). RECENT FINDINGS: Apheresis is the most efficacious method to lower Lp(a). Currently, there are no approved drugs to specifically lower Lp(a). However, recent data has demonstrated that Lp(a) can be significantly lowered, along with reductions in other apolipoprotein B-100 (apoB) containing lipoproteins, with antisense oligonucleotides to apoB, monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, cholesterol ester transfer protein inhibitors, and thyromimetics. The farnesoid X receptor/fibroblast growth factor axis and interleukin-6 also influence Lp(a) levels and may be targets of therapy. Finally, specific apolipoprotein (a) [apo(a)] inhibitors apo(a) have been developed and reduce apo(a) mRNA and protein levels up to 86% without significantly affecting other lipoproteins. SUMMARY: Lp(a) remains the last major lipoprotein disorder without any specific therapy. With the strong and accumulating data on its role as a causal risk factor for CVD, a rationale exists to develop novel agents to reduce Lp(a) and test the hypothesis that this will lead to reduced CVD events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G. (2004) · Circulation · doi:10.1161/01.cir.0000141728.23033.b5 · Cited by 225
Self-citationSamaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J., & Rader, D. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1250 · Cited by 220
Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156
Self-citation
Cited by
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 674
Self-citationReduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
Willeit, P., Kiechl, S., Kronenberg, F., Witztum, J. L., Santer, P., Mayr, M., Xu, Q., Mayr, A., Willeit, J., & Tsimikas, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.061 · Cited by 286
“Cholesterol ester transferase protein (CETP) inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies currently in trials also lower Lp(a) up to 40% (21,37).”
BackgroundSelf-citationLangsted, A., Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30042-0 · Cited by 270
The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis
Hurtubise, J., McLellan, K., Durr, K., Onasanya, O., Nwabuko, D., & Ndisang, J. F. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0632-z · Cited by 255
Metadata
- Authors
- Kolski, B., & Tsimikas, S.
- Venue
- Current Opinion in Lipidology
- Published
- 2012-12
- Volume
- 23
- Issue
- 6
- Pages
- 560-568
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2328235549
- Cited by
- 63
- References
- 12
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging therapeutic agents to lower lipoprotein (a) levels. https://app.cochat.ai/papers/10.1097/mol.0b013e3283598d81
- The paper
- Kolski, B., & Tsimikas, S. (2012). Emerging therapeutic agents to lower lipoprotein (a) levels. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0b013e3283598d81
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.